14. Late Pulmonary Complications after Allogeneic Hematopietic Stem Cell Transplantion: Bronchiolitis Obliterans Syndrome (BOS) and Organizing Pneumonia (OP)

  1. Bipin N Savani MD
  1. Lee Gazourian1,
  2. Gerald L Weinhouse1,
  3. Joseph H Antin2 and
  4. Vincent T Ho2

Published Online: 6 SEP 2013

DOI: 10.1002/9781118473306.ch14

Blood and Marrow Transplantation Long-Term Management: Prevention and Complications

Blood and Marrow Transplantation Long-Term Management: Prevention and Complications

How to Cite

Gazourian, L., Weinhouse, G. L., Antin, J. H. and Ho, V. T. (2013) Late Pulmonary Complications after Allogeneic Hematopietic Stem Cell Transplantion: Bronchiolitis Obliterans Syndrome (BOS) and Organizing Pneumonia (OP), in Blood and Marrow Transplantation Long-Term Management: Prevention and Complications (ed B. N. Savani), John Wiley & Sons, Ltd, Oxford, UK. doi: 10.1002/9781118473306.ch14

Editor Information

  1. Professor of Medicine,Director, Long Term Transplant Clinic, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center, Nashville, TN, USA

Author Information

  1. 1

    Division of Pulmonary Medicine, Brigham and Women's Hospital, Boston, MA, USA

  2. 2

    Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

Publication History

  1. Published Online: 6 SEP 2013
  2. Published Print: 1 OCT 2013

ISBN Information

Print ISBN: 9781118473405

Online ISBN: 9781118473306

SEARCH

Keywords:

  • transplantation;
  • bronchiolitis obliterans;
  • BOS;
  • pneumonia;
  • organizing pneumonia;
  • stem cell;
  • pulmonary complication;
  • COP;
  • bone marrow transplantation

Summary

Pulmonary complications following allogeneic hematopoietic stem cell transplantation (HSCT) result in significant increase in transplant-related morbidity and mortality. Bronchiolitis obliterans syndrome (BOS) and cryptogenic organizing pneumonia (COP) are the two most common noninfectious late-onset pulmonary complications following HSCT. BOS is an irreversible form of airflow obstruction that can progress to respiratory failure and death. COP is an inflammatory lung disease; unlike BOS, COP is commonly responsive to therapy. This chapter will focus on the prevalence, monitoring, prevention, and management of BOS and COP.